Neurocrine Biosciences (NBIX) EBT Growth (5y) (2015 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) EBT Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 23.05% |
| Mar 31, 2026 | 55.44% |
| Dec 31, 2025 | 41.84% |
| Sep 30, 2025 | 48.04% |
| Jun 30, 2025 | 13.90% |
| Mar 31, 2025 | -17.69% |
| Dec 31, 2024 | 33.32% |
| Sep 30, 2024 | 26.65% |
| Jun 30, 2024 | 13.61% |
| Mar 31, 2024 | 18.50% |
| Dec 31, 2023 | 60.23% |
| Sep 30, 2023 | 17.89% |
| Jun 30, 2023 | 86.50% |
| Mar 31, 2023 | -19.82% |
| Dec 31, 2022 | 76.44% |
| Sep 30, 2022 | 60.95% |
| Jun 30, 2022 | 17.47% |
| Mar 31, 2022 | 17.82% |
| Dec 31, 2021 | 19.99% |
| Sep 30, 2021 | 22.94% |